Adalimumab >+MTX (DE009) | Adalimumab >+MTX >(DE009 and DE019) | Etanercept >+MTX | Infliximab >+MTX | Adalimumab monotherapy | Etanercept monotherapy | Traditional DMARDs | |
---|---|---|---|---|---|---|---|
ACR50/DAS28 good | |||||||
Drug | 48948 | 41407 | 41140 | 29859 | 24706 | 39423 | 3962 |
Direct | 39317 | 40479 | 41271 | 48863 | 44153 | 41507 | 46145 |
Monitoring/adverse events | 20717 | 20723 | 20718 | 23376 | 21199 | 21491 | 20280 |
Total cost | 108982 | 102610 | 103129 | 102099 | 90058 | 102421 | 70387 |
Total QALY | 2.3114 | 2.1045 | 2.0974 | 1.8379 | 1.6551 | 2.0493 | 1.1818 |
Incremental cost v traditional DMARD | 38595 | 32222 | 32742 | 31711 | 19671 | 32034 | – |
Incremental QALY v traditional DMARD | 1.1296 | 0.9227 | 0.9156 | 0.6560 | 0.4733 | 0.8675 | – |
Incremental cost per QALY v traditional DMARD | 34167 | 34922 | 35760 | 48333 | 41561 | 36927 | – |
ACR20/DAS28 moderate | |||||||
Drug | 61306 | 56853 | 65517 | 44247 | 43860 | 55042 | 5816 |
Direct | 36246 | 37186 | 44611 | 45371 | 48721 | 36988 | 43218 |
Monitoring/adverse events | 20428 | 20424 | 23462 | 25114 | 23861 | 20320 | 19724 |
Total cost | 117979 | 114462 | 133590 | 114732 | 116442 | 112351 | 68757 |
Total QALY | 2.9083 | 2.7424 | 2.9515 | 2.4121 | 2.4321 | 2.7303 | 1.7041 |
Incremental cost v traditional DMARD | 49221 | 45705 | 64832 | 45974 | 47685 | 43593 | – |
Incremental QALY v traditional DMARD | 1.2042 | 1.0383 | 1.2474 | 0.7080 | 0.7280 | 1.0262 | – |
Incremental cost per QALY v traditional DMARD | 40875 | 44018 | 51976 | 64935 | 65499 | 42480 | – |